PL369104A1 - Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease - Google Patents
Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart diseaseInfo
- Publication number
- PL369104A1 PL369104A1 PL02369104A PL36910402A PL369104A1 PL 369104 A1 PL369104 A1 PL 369104A1 PL 02369104 A PL02369104 A PL 02369104A PL 36910402 A PL36910402 A PL 36910402A PL 369104 A1 PL369104 A1 PL 369104A1
- Authority
- PL
- Poland
- Prior art keywords
- inhibitors
- heart disease
- myocardial dysfunction
- structural heart
- treat myocardial
- Prior art date
Links
- 102000019025 Calcium-Calmodulin-Dependent Protein Kinases Human genes 0.000 title 1
- 108010026870 Calcium-Calmodulin-Dependent Protein Kinases Proteins 0.000 title 1
- 230000004064 dysfunction Effects 0.000 title 1
- 208000019622 heart disease Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000002107 myocardial effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32657601P | 2001-10-01 | 2001-10-01 | |
| US32801001P | 2001-10-08 | 2001-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL369104A1 true PL369104A1 (en) | 2005-04-18 |
Family
ID=26985461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL02369104A PL369104A1 (en) | 2001-10-01 | 2002-10-01 | Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7320959B2 (enExample) |
| EP (1) | EP1439849A4 (enExample) |
| JP (1) | JP2005504829A (enExample) |
| KR (1) | KR20040045041A (enExample) |
| CN (1) | CN1599622A (enExample) |
| AU (1) | AU2002341938B2 (enExample) |
| BR (1) | BR0213043A (enExample) |
| CA (1) | CA2462443A1 (enExample) |
| IL (1) | IL161231A0 (enExample) |
| MX (1) | MXPA04003040A (enExample) |
| NO (1) | NO20041331L (enExample) |
| NZ (1) | NZ532327A (enExample) |
| PL (1) | PL369104A1 (enExample) |
| WO (1) | WO2003029428A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080255121A1 (en) * | 2004-11-02 | 2008-10-16 | Dainippon Sumitomo Pharma Co., Ltd. | Combination Drug for Treating Autoimmune Disease |
| CN107402307A (zh) * | 2008-04-09 | 2017-11-28 | B.R.A.H.M.S 有限公司 | 用于预测受损峰值耗氧量的内皮素1原 |
| US8841423B2 (en) * | 2008-04-28 | 2014-09-23 | University Of Iowa Research Foundation | Monoclonal antibodies specific for oxidized calcium/calmodulin dependent protein kinase II |
| US20090275514A1 (en) * | 2008-05-01 | 2009-11-05 | Anderson Mark E | Use of calmodulin kinase ii inhibitors to treat or prevent heart muscle inflammation |
| WO2010135676A1 (en) * | 2009-05-22 | 2010-11-25 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Engineered biological pacemakers |
| US8440656B2 (en) * | 2009-06-22 | 2013-05-14 | University Of Iowa Research Foundation | Methods of treating pulmonary diseases and disorders by modulating calcium/calmodulin dependent protein kinase II activity |
| EP3603658B1 (en) | 2009-10-05 | 2025-01-08 | Cornell University | Peptide for use in the treatment of heart failure resulting from hypertrophic cardiomyopathy |
| CN105517549B (zh) | 2013-03-06 | 2018-11-23 | 阿略斯泰罗斯医疗公司 | CaMKII抑制剂和其用途 |
| DE102014201651A1 (de) * | 2014-01-30 | 2015-07-30 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Isoxazolderivate zur Verwendung bei der Behandlung und/oder Prophylaxe von Herzerkrankungen |
| CA2960101C (en) | 2014-09-05 | 2024-05-21 | Allosteros Therapeutics, Inc. | Substituted carboline derivative and compositions thereof useful as camkii inhibitors |
| WO2018031771A1 (en) | 2016-08-11 | 2018-02-15 | University Of Iowa Research Foundation | CATIONIC CaMKII INHIBITING NANOPARTICLES FOR THE TREATMENT OF ALLERGIC ASTHMA |
| CN112972447B (zh) * | 2021-03-02 | 2022-09-23 | 扬州大学附属医院 | CaMK II抑制剂在制备预防和/或治疗急性胰腺炎的药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1601438A (enExample) * | 1968-10-17 | 1970-08-24 | ||
| US4897355A (en) * | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| JP2001509808A (ja) * | 1997-01-31 | 2001-07-24 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | 多機能性カルシウム／カルモジュリン−依存性プロテインキナーゼの阻害による不整脈の処置 |
| JP2963986B2 (ja) * | 1997-11-19 | 1999-10-18 | 工業技術院長 | カルモジュリン依存性リン酸化酵素ｉｉの特異的阻害剤 |
-
2002
- 2002-10-01 MX MXPA04003040A patent/MXPA04003040A/es not_active Application Discontinuation
- 2002-10-01 JP JP2003532646A patent/JP2005504829A/ja active Pending
- 2002-10-01 CA CA002462443A patent/CA2462443A1/en not_active Abandoned
- 2002-10-01 NZ NZ532327A patent/NZ532327A/en unknown
- 2002-10-01 WO PCT/US2002/031496 patent/WO2003029428A2/en not_active Ceased
- 2002-10-01 AU AU2002341938A patent/AU2002341938B2/en not_active Ceased
- 2002-10-01 PL PL02369104A patent/PL369104A1/xx not_active Application Discontinuation
- 2002-10-01 KR KR10-2004-7004775A patent/KR20040045041A/ko not_active Withdrawn
- 2002-10-01 EP EP02776099A patent/EP1439849A4/en not_active Withdrawn
- 2002-10-01 IL IL16123102A patent/IL161231A0/xx unknown
- 2002-10-01 BR BR0213043-2A patent/BR0213043A/pt not_active IP Right Cessation
- 2002-10-01 US US10/491,323 patent/US7320959B2/en not_active Expired - Fee Related
- 2002-10-01 CN CNA028241010A patent/CN1599622A/zh active Pending
-
2004
- 2004-03-31 NO NO20041331A patent/NO20041331L/no not_active Application Discontinuation
-
2007
- 2007-11-13 US US11/983,987 patent/US7632815B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1439849A2 (en) | 2004-07-28 |
| BR0213043A (pt) | 2004-10-05 |
| US7632815B2 (en) | 2009-12-15 |
| NZ532327A (en) | 2005-10-28 |
| AU2002341938B2 (en) | 2007-08-30 |
| US20090011989A1 (en) | 2009-01-08 |
| NO20041331D0 (no) | 2004-03-31 |
| WO2003029428A8 (en) | 2004-04-22 |
| US20040266675A1 (en) | 2004-12-30 |
| NO20041331L (no) | 2004-05-28 |
| CN1599622A (zh) | 2005-03-23 |
| US7320959B2 (en) | 2008-01-22 |
| WO2003029428A3 (en) | 2003-10-30 |
| WO2003029428A2 (en) | 2003-04-10 |
| MXPA04003040A (es) | 2004-07-15 |
| EP1439849A4 (en) | 2005-09-28 |
| JP2005504829A (ja) | 2005-02-17 |
| KR20040045041A (ko) | 2004-05-31 |
| IL161231A0 (en) | 2004-09-27 |
| CA2462443A1 (en) | 2003-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL161231A0 (en) | Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease | |
| TW200607803A (en) | Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto | |
| EP1689393A4 (en) | PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | |
| AU5523701A (en) | Methods of using growth factors for treating heart disease | |
| IL148719A0 (en) | Kinase inhibitors as therapeutic agents | |
| ZA200704476B (en) | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases | |
| EP1670466A4 (en) | PREPARATION OF 1,6,7-TRISUBSTITUTED AZABENIC ZIMIDAZOLES AS KINASE-INHIBITORS | |
| IL160928A0 (en) | Use of histamine to treat liver disease | |
| NO20015112D0 (no) | Anvendelse av glykosylceramidsynteseinhibitorer ved terapi | |
| HUP0301244A3 (en) | Use of rapamycin for preparation of pharmaceutical composition to treat heart and cardiovascular diseases | |
| ZA200106197B (en) | Use of glycogen phosphorlase inhibitors to inhibit tumor growth. | |
| AU2756701A (en) | Use of low dosage bisphosphonates to inhibit cardiac and arterial calcification | |
| HRP20030874A2 (en) | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases | |
| EP1373221A4 (en) | NOVEL CYANO SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THERATEUTIC USE THEREOF | |
| HUP0004780A3 (en) | Use of prostaglandin agonists to treat erectile dysfunction or impotence | |
| GB0023915D0 (en) | Treatment of neuroinflammatory disease | |
| GB0328497D0 (en) | Compounds which bind to the active site of protein kinase enzymes | |
| HK1067059A (en) | Use of calmodulin kinase ii inhibitors to treat myocardial dysfuction in structural heart disease | |
| EP1472282A4 (en) | USE OF CALMODULIN TO PROMOTE BONE REGENERATION | |
| NO20033541L (no) | Anvendelse av fosfodiesteraseinhibitorer av type 4 ved hjertemuskelsykdommer | |
| SI1176981T1 (sl) | Zdravljenje avtoimunskih bolezni z antagonisti, ki se vezejo na B celicne povrsinske markerje | |
| IL149561A0 (en) | Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue | |
| GB2410744B (en) | Kinase inhibitors for the treatment of disease | |
| IL155814A0 (en) | Treatment of sexual dysfunction using bombesin antagonist | |
| HK1063729A (en) | Use of histamine to treat liver disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |